Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into ... Read ...

A new study reveals that fragmented sleep causes cellular damage to the brain's blood vessels, providing further evidence to ...